MOUNTAIN VIEW, CA--(Marketwired - September 21, 2015) - Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it will exhibit its Magellan™ Robotic System at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Scientific Meeting September 26-September 30 at Centro de Congressos de Lisboa in Lisbon, Portugal. The Company will showcase the Magellan 6Fr Robotic Catheter that is used by Interventional Radiologists in embolization procedures and will conduct Magellan Robotic System demonstrations at exhibit booth #54.
The meeting marks the 30th anniversary of CIRSE and is the largest IR event of 2015. During this year's CIRSE meeting, Hansen Medical will host an educational speaker series at the Magellan booth to discuss how intravascular robotics is helping to advance embolization procedures and reduce radiation exposure. This series includes the following sessions:
- September 26, 11:00- Incorporating Intravascular Robotics in Embolization- Marc Sapoval, MD, PhD (Paris, France)
- September 26, 12:30 & September 27, 11:00- Experiences with Robotic Assisted UFE- Mohamad Hamady, MD (London, UK)
- September 27, 09:30 & September 28, 11:00- Update on PAE and Role for Robotics- Sandeep Bagla, MD (Alexandria, Virginia)
- September 28, 09:30- Robotic Catheter Assistance: The Relationship on Radiation Exposure- Barry Katzen, MD (Miami, Florida)
Hansen Medical is also highlighting its dedication to reducing radiation exposure for physicians, staff and patients. Hansen Medical is a sponsor of the second annual Radiation Protection Pavilion, which is an interactive awareness campaign for radiation protection and dose management in interventional radiology. At the pavilion, Dr. Katzen will discuss the role of robotic technology in reducing radiation exposure and will present on September 28 at 2:00pm local time.
Magellan is also featured in CIRSE's Product Launch portfolio, which highlights new data presented by Sandeep Rao, MD and Dr. Katzen indicating a greater than 90% physician radiation reduction during robotic-assisted endovascular procedures, as compared to manually performing a procedure at the bedside.
"We are looking forward to meeting with the CIRSE community and seeing Magellan physician users from around the world at the largest global Interventional Radiology meeting," said Cary Vance, Hansen Medical's President and Chief Executive Officer. "Current radiation reduction initiatives and recent advances in embolization procedures across Women's Health, Men's Health and Cancer treatments speak to a high level of innovation within the IR community. We are excited about the role that Magellan has had in these efforts and that Magellan has enabled physicians and patients to benefit from robotic precision, control and protection during embolization procedures."
About the Magellan™ Robotic System
Hansen Medical's Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedures globally. The Magellan Robotic System offers several important features including:
- Provides predictability, control and catheter stability as a physician navigates a patient's peripheral vasculature and then provides a conduit for manual treatment of vascular disease with standard therapeutic devices.
- Is designed to enable more predictable procedure times and increased case throughput potentially allowing hospitals to improve utilization within their vascular business line.
- Employs an open architecture designed to allow for the subsequent use of many therapeutic devices on the market today.
- Is designed to potentially reduce physician radiation exposure and fatigue by allowing the physician to navigate procedures while seated comfortably at a remote workstation away from the radiation field and without wearing heavy lead as required in conventional endovascular procedures.
- The Magellan 9Fr and 10Fr Robotic Catheters allow for independent, robotic control of two telescoping catheters (an outer Guide and an inner Leader catheter), as well as robotic manipulation of standard guide wires.
- The Magellan 6Fr Robotic Catheter allows for independent robotic control of two separate bend sites on a single catheter, as well as robotic manipulation of standard guide wires. This smaller catheter design may be preferred by certain physicians who prefer a smaller diameter vessel access site, or in procedures in smaller vessels.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is the global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, Magellan Robotic Catheters, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Company's mission is to enable cardiac arrhythmia and endovascular procedures and to improve patient outcomes through the use of intravascular robotics. Additional information can be found at www.hansenmedical.com.
"Hansen Medical," "Hansen Medical (with Heart Design)," and "Heart Design (Logo)" are registered trademarks, and "Magellan" and "Hansen Medical Magellan" are trademarks of Hansen Medical, Inc. in the U.S. and other countries. All other trademarks are the property of their respective owners.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and other similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements regarding the potential benefits of our robotic systems for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: factors relating to engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the rate of adoption of our systems and the rate of use of our catheters; our ability to manage expenses and cash flow, and obtain adequate financing; and other risks more fully described in the "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2014, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Help employers find you! Check out all the jobs and post your resume.
